The therapeutic potential of targeting the CHD protein family in cancer

Min Zhang, Kaiyuan Wu, Weijie Zhang, Xia Lin, Qi Cao, Lili Zhang, Kaifu Chen

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Accumulating evidence indicates that epigenetic events undergo deregulation in various cancer types, playing crucial roles in tumor development. Among the epigenetic factors involved in the epigenetic remodeling of chromatin, the chromodomain helicase DNA-binding protein (CHD) family frequently exhibits gain- or loss-of-function mutations in distinct cancer types. Therefore, targeting CHD remodelers holds the potential for antitumor treatment. In this review, we discuss epigenetic regulations of cancer development. We emphasize proteins in the CHD family, delving deeply into the intricate mechanisms governing their functions. Additionally, we provide an overview of current therapeutic strategies targeting CHD family members in preclinical trials. We further discuss the promising approaches that have demonstrated early signs of success in cancer treatment.

Original languageEnglish (US)
Article number108610
JournalPharmacology and Therapeutics
Volume256
DOIs
StatePublished - Apr 2024

Keywords

  • Cancer development
  • Chromatin remodeling
  • Epigenetic regulation
  • Therapeutic strategies

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'The therapeutic potential of targeting the CHD protein family in cancer'. Together they form a unique fingerprint.

Cite this